600196

2019

MeiStar		MeiStar Limited
MimiVax		MimiVax, LLC

		Fosun Industrial Co., Limited
		( )
		01099
		600837 00665
		002099
		002412 600276

		000513
FDA		U.S.Food and Drug Administration
		3SBio, Inc. 01530
		300452
		601607

	Shanghai Fosun Pharmaceutical Group Co., Ltd.
	FOSUNPHARMA

	1289 A	1289 A
	021-33987870	021-33987870
	021-33987871	021-33987871
	ir@fosunpharma.com	ir@fosunpharma.com

	510 9
	200063
	1289 A
	200233
	http://www.fosunpharma.com

ir@fosunpharma.com

		1 22
		7 15
		2015 7
		388 28
		2015 7

2019 1 11

2019 5 11

2019 10 26

2019 12 21

	2019	2018	(%)	2017
	28,585,152,033.18	24,918,273,561.40	14.72	18,533,555,418.42
	3,321,617,566.05	2,707,923,418.34	22.66	3,124,499,549.35
	2,233,957,491.68	2,089,792,463.26	6.90	2,345,909,050.39
	3,222,412,571.25	2,950,105,213.40	9.23	2,580,225,775.68
	2019	2018	%	2017
	31,888,066,063.03	27,977,736,427.49	13.98	25,326,868,055.50
	76,119,645,663.32	70,551,361,387.48	7.89	61,971,008,797.38

	2019	2018	(%)	2017
/	1.30	1.07	21.50	1.27
/	1.30	1.07	21.50	1.27
/	0.87	0.83	4.82	0.95
%	11.55	10.26	1.29	13.02
%	7.77	7.92	0.15	9.77

□ √

□ √

√ □

ê"A 1

2019

	1-3	4-6	7-9	10-12
	6,730,014,185.66	7,442,754,435.11	7,054,850,058.34	7,357,533,354.07
	712,291,660.86	803,828,186.09	547,584,301.04	1,257,913,418.06
	529,562,795.43	638,041,090.77	554,784,142.14	
	408,188,793.29	1,041,998,757.20	878,168,233.68	

□ √

√ □

	2019	2018	2017
	1,709,222,521.25	392,177,190.57	386,662,410.46
	137,859,803.94	113,511,501.09	54,145,031.51
	-277,347,931.16	272,152,473.60	619,352,961.69
	30,092,620.17	44,059,042.08	-16,703,333.29
	-71,951,143.37	-	-18,706,000.00
	-52,463,591.32	-33,651,666.46	-17,149,053.65
	-387,752,205.14	-170,117,585.80	-229,011,517.76
	1,087,660,074.37	618,130,955.08	778,590,498.96

√ □

	616,123,764.39	456,650,637.52	-159,473,126.87	-24,708,272.51
	2,505,806,955.75	1,983,154,536.18	-522,652,419.57	-318,731,427.10
	126,313,106.69	107,709,225.73	-18,603,880.96	-
	-	9,719,292.86	-9,719,292.86	-9,719,292.86
	3,248,243,826.83	2,557,233,692.29	-710,448,720.26	-353,158,992.47

□ √

34.63

2018 38.15%

5,300 1,000

2 CAR-T

31.31 2018 39.12%

264 19

12 21 133 49 2

28 8 20

3

Tridem Pharma

4

SAP

2

373,581.15 2018 2.66%

28.52% “ ”

Sisram

HPV

3

303,992.27 2018 18.61%

/

“ ” FDA

POCT

HPV 2019

HPV

Glycotest

Sisram

÷

=

2019-2022 2019 1427

2019

2019 9 “ ”

2019

2019 30 2019

2019 33

“ ”

2

2019

“ ”

2020 “ ”

2019

25 <

>

2019 44

ICH

“ ”

3

2019 “ 4+7 ”

2019 3 “ ”

“ 4+7 ”

“ 4+7 ”

2019 56

“ 4+7 ” 33

6

4

2019

2019 45 2019

125

“ ”

2019 2019 61

2019 210

2019 39 2019 2019

802

2019 42

2019 55

“ ”

“ + ”

2019 80

2019 236

5

2019 8 2019 46

11 < >

2019 65 12 2019

2019

2019 2019

6

2019 34 10 DRG

2019 36

2019 55

6

/

/

“ ”

/

√ □

1

7,611,964.57 7.89%

2,040,336.75 13.34%

H

5,571,627.82 6.03% “

” “ ”

1,922,238.76 25.25%

2

Gland Pharma

Sisram Tridem Pharma

Breas Gland Pharma FDA

GMP Sisram

Tridem Pharma

21

/

/

1,000 Tridem Pharma

√ □

“ ”

“ ”

2,858,515.20 2018 14.72%

2,176,587.34 2018 16.51%

373,581.15 2018 2.66% 28.5%

303,992.27 2018 18.61%

2,196,333.55 2018 15.52%

662,181.65 2018 12.12%

23.17%

[1]	2,176,587.34	1,868,134.51	16.51
[2]	373,581.15	363,886.91	2.66
[3]	303,992.27	256,296.75	18.61

“ ”

374,352.13 332,161.76

223,395.75 2018

23.96% 22.66% 6.90% 1

16.51%

2019 5 1.5

2019 35 6

18% Gland Pharma

52.2% Gland Pharma

44.8% 2

“ ” 2019 60

4 HPV 3

HHH

2019

322,241.26 2018 9.23%

34.63 38.15%

20.41 37.97% 31.31

39.12% 14.38%

2,176,587.34 2018

16.51% 192,484.16 2018 7.84% 207,296.05

2018 18.12%

2019

105% 113% 57%

2019 5 1.5

	381,589.39	322,245.47	18.42
	62,020.23	50,000.88	24.04
	444,926.41	396,483.26	12.22
	218,893.68	177,381.92	23.40

	229,426.20	190,140.80	20.66
	85,446.32	71,079.90	20.21
	113,587.14	130,143.66	-12.72

“ ”

31.31 39.12% 14.38%

17.41 38.72% 8.00%

2,200 7%

264 19 12 21

133 49 2 28

8 20 8 32

38 136

13 3 7 PCT 6

47 2019 35 6

10 3 5 10

7

2019 CAR-T

9 1 9

3 3 ORIN1001 I

FDA

2

12 8

20

FKC876 CD19 CAR-T B

2020 3

3	PA-824		I	-	-
4	FN-1501		I		I
5	FCN-437		I		I
6			I	-	-
7	FCN-159		I	-	-
8	ORIN1001( )		I		I
9			I	-	-

FDA Fast Track Development Program 2020 1

1			[1]	-	-	-
2				III	[2]	III
3				III	-	-
4		VEGF		III	-	-
5		EGFR		-	-	-
6					-	-
7		VEGFR2 II-III		I	-	-
8		CD20		III [3]	-	-
9		VEGF		-	-	-
10		VEGFR2 [4]		I		-
11		EGFR [5]		Ib/II Ia		-
12		PD-1	[6]	II		-
13		PD-L1		-	[7]	I

14		HLX22		I	-	-
15					-	-
16		PD-1 VEGF		III	-	-

8 PD-1 VEGF

III

II I

1		PA-824	/ XDR-TB MDR-TB		I
2					III
					-
					-
3		Tenapanor			-
					-
4		Bremelanotide			-
5		Opicapone			I
6					I
7		Fortacin			-
8	1	RT002			-
					-

OOS CAPA

“ FOPEX ”,

GMP

WHO cGMP

cGMP Gland Pharma

GMP / 1 3 WHO-PQ

1 FDA 1

cGMP 1 FDA cGMP

373,581.15 2018 2.66%

57,439.07 2018 2.91% 49,542.96

2018 12.67% 1 “

” 2019 60 4 2

HPV

Sisram

2019

Sisram 4 CE Soprano Titanium Colibri

Soprano Titanium

Colibri 2019 Sisram

17,352.00 2,193.50 2018 12.73% 0.48%

Sisram

2019 HPV 2018

31

Glycotest

2019 4,25

106 6 23.44% 12.93% 7.14%

2019 3,373 20.02%

30

6,204 2019

198 33.77%

2019 69

40.06%

HIS

HRP

S2B2C 5G AI

2019 48.5% 3.89

34

18

2.90% 4

“ ”

2,400

2019

“ ”

2019

“ ” 10

“ ” , 2016 4,000

“ ”

“ ” “ ”

Gland Fosun Foundation

2019 .

.

2.

√ □

(1).

			%	%	%	%
	2,176,587.34	747,884.19	65.64	16.51	14.67	0.55
	373,581.15	177,904.25	52.38	2.66	-5.77	4.27
	303,992.27	226,407.31	25.52	18.61	19.92	0.82
			%	%	%	%
1	381,589.39	59,683.69	84.36	18.42	5.98	1.84
2	62,020.23	19,345.08	68.81	24.04	41.46	3.84
3	444,926.41	126,939.17	71.47	12.22	18.48	1.51
4	218,893.68	11,118.16	94.92	23.40	15.20	0.36
5	229,426.20	82,464.87	64.06	20.66	33.72	3.51
6	85,446.32	4,718.80	94.48	20.21	40.26	0.79
7	113,587.14	83,146.52	26.80	-12.72	-12.68	0.03
			%	%	%	%
	2,196,333.55	762,686.63	65.27	15.52	12.97	0.78
	662,181.65	391,655.48	40.85	12.12	8.36	2.05

1 18.42%

2 24.04%

3	12.22%
4	23.40%
5	20.66%

			(%)		(%)	(%)
		59,683.69	7.98	56,316.67	8.63	5.98
		19,345.08	2.59	13,675.51	2.10	41.46
		126,939.17	16.97	107,142.66	16.43	18.48
		11,118.16	1.49	9,651.05	1.48	15.20
		82,464.87	11.03	61,669.88	9.46	33.72
		4,718.80	0.63	3,364.29	0.52	40.26
		83,146.52	11.12	95,225.17	14.60	-12.68

(4).

√ □

591,959.98 20.71

358,304.15 12.53

109,119.93 9.95

26,370.20 2.40

3.

√ □

984,675.84 2018 16.01%

204,140.06	2018	37.97%
86,543.88	2018	19.50%

4.

“ ” “ ”

√ □

	20.41
	14.22
	34.63
%	12.12
%	14.38
	2,147
%	6.84
%	41.05

√ □

31.31 39.12% 14.38%

5.

√ □

	322,241.26	295,010.52	9.23	
	-17,196.28	-524,491.48	96.72	HHH
	-193,597.83	313,753.43	-161.70	HHH

( )

□ √

( )

√ □

1.

		%		%	%	
	24,012.23	0.32	71,251.06	1.01	-66.30	

“ ”

52,479.66 0.69 - -

“ ”

2.

□ √

3.

□ √

( )

1.

(1).

√ □

“ ” “ ”

(2).

√ □

√ □

√ □

									2019	2019
	40mg*16s/					2006.12-2026.12			1,069	1,087
	(0.6g/)				(	2006.5-2026.5			8,212	7,024

					)					
	1.0g/								2,902	2,857
	5ml/				1 2 3				5,695	5,492
									9,608	9,075

(3).

√ □

(2).

□ √

√ □

		[1]	[1]
	389,633.60	16.73%	17.42%
	82,772.99	8.82%	6.89%
	53,393.70	3.63%	4.44%
	150,876.63	6.42%	3.15%
	40,648.70	5.51%	5.37%
[2]			143,465.12
			346,322.78
			12.12
			14.38
			8.83

□ √

(3).

√ □

1		1.1		I	8,584.00	1	0	
2	FCN-411	1.1		I	4,801.20	1	0	
3	FCN-437	1 /505(i)		I	7,827.68	1	0	

4	FCN-159	1		I	3,703.09	1	0	
5	FN-1501	1		I	7,789.75	1	0	
6		1		I	4,957.16	1	0	
7	ORIN1001	1 /505(i)		I	6,687.00	1	0	
8		2.2		I	2,806.69	4	0	
9	CD20	2			57,320.78	17	2	
10	CD20	1		III		1	0	
11	HER2	2		III	70,249.32	15	1	
12	TNF α	2		III	24,988.65	19	3	
13	VEGF	2		III	40,411.81	20	2	
14	VEGF	1		-		1	0	
15	VEGFR2 II-III	2		I	5,867.26	7	0	
1	VEGFR2	1		I	8,392.85	1	0	
1	PD-1	1		III	45,828.62	1	0	
1	EGFR	1		Ib/II Ia	15,838.71	1	0	

2	HER2 F	1		I	11,328.28	1	0	
2	-HyFc	1		I	5,007.47	1	0	
2		15		III	16,838.80	3	2	
2	50R	15		III		3	1	
2		15		III	10,239.10	9	4	
2		10		I	4,959.85	11	1	
2		15		III	8,490.54	9	6	
		6		III	5,844.17	1	0	
3	[1]	2.4		III	3,792.57	1	0	
3	[2]	5.1		-		1	0	
3	[illegible]	[illegible]		[illegible]	3,523.78	1	0	

2	FCN-647	1	B
3	ORIN1001	1	
4	Bremelanotide	1	
5	Tenapanor	1	
6	Tenapanor	2.4	
7		2.4	
8	HLX55	1	
9	HLX10(PD-1) HLX07 EGFR		
10	HER2 II	2	HER2
11	-HyFc	1	

505(i)

1	FCN-437	1 /505(i)	
2	ORIN1001	1 /505(i)	
3	Bremelanotide	1	
4	Tenapanor	1	
5		2.4	
6	HLX55	1	
7	HLX10(PD-1) HLX07 EGFR		
8	-HyFc	1	

505(i)

1		2	
2		2	

1		2	

1	0.3g		

2			2
3	0.1g		
4	0.3g		
5			
6			β
7			
8			

(5).

□ √

(6).

√ □

				2020
1	TNF α		2	
2	HER2		2	
3	VEGF		2	III
4	PD-1		1	III
5			1.1 /505(i)	II
6	FCN-437		1 /505(i)	I
7	FN-1501		1 /505(i)	I
8	FCN-159		1	I
9	ORIN1001		1 /505(i)	I
10	FCN-411		1.1	I
11	VEGFR2 II-III		2	I
12	CD20		1	III
13			15	III
14			15	III
15	50R		15	III
16			10	I

17	-HyFc		1	I
18			2.4	III
19			5.1	
20			5.1	I

(7).

I II / III /

(8).

1	———		2,290	0
2	“ ”		2,093	2,093
3	2018		1,819	1,819
4	2019 ( )---		1,500	1,500
5			921	921
6	2019 ——— 75mg 150mg 2.5mg		720	720
7	2019 - -- OAV		685	595
8	2019 ——— 0.5mg 1.0mg		600	600
9	2019 ——— 1.0g 1.5g		590	590

10	2019 -- JITRI--		300	100

(9).

1							
2							

3.

(1).

√ □

			(%)	%	%	%	%
	381,589.39	59,683.69	84.36	18.42	5.98	1.84	80.86
	62,020.23	19,345.08	68.81	24.04	41.46	-3.84	93.96
	444,926.41	126,939.17	71.47	12.22	18.48	-1.51	46.05
	218,893.68	11,118.16	94.92	23.40	15.20	0.36	83.99
	229,426.20	82,464.87	64.06	20.66	33.72	-3.51	72.73
	85,446.32	4,718.80	94.48	20.21	40.26	-0.79	75.91
	113,587.14	83,146.52	26.80	-12.72	-12.68	-0.03	30.99

√ □

2018

2019 “

”

2019

“ ”

2019

“ ”

2019

“ ”

2018

“ ”

2019 “ ”

(2).

√ □

5,300

1,000

Tridem Pharma

800

(3).

√ □

			/
	40mg	6.64-24.35	4,991
	80mg	15.95-42.83	96
	0.3g	8.7-10.45	154
	0.6g	12.68-16.8	2,629

	0.9g	20.18-22.9	614
	1.0g	21.76-25.22	428
	1.2g	21.74-28.9	901
	1.5g	30.19-34.8	84
	1.8g	35.07-35.241	29
	0.25g	14.11-17.4133	136
	0.5g	20-28,84	1,993
	1.0g	35.775-46.63	1,538
	5ml:0.2g	34.12-54.2	2,019
	10ml:0.4g	58-92.4	1,247
	20ml:0.8g	98.66-118	66
	40mg	45.44-68	174
	2ml:12500	4.95-11.6	2,502
	5000IU	19.55-21.44	804
	2500IU	11.65-15	186

IQVIA

□ √

(4).

√ □

		%
	122,562.52	12.45
	754,089.77	76.58
	31,076.30	3.16
	24,382.44	2.48
	20,757.14	2.11
	7,847.51	0.80
	23,960.16	2.42
	984,675.84	100.00

√ □

	[1]	[1] %
	852,496.76	36.61

	309,321.98	32.96
	373,025.62	39.76
	655,027.62	44.55
	252,244.45	34.21
[2]		488,423.29
[3] %		37.62
		984,675.84
%		34.45

1 5 2019

2 5 2019

3 5 2019

□ √

4.

□ √

( )

1

√ □

	201,181.17
	585,005.28
	-383,824.11
%	-65.61

(1)

√ □

2019 1 15

“ ” 17,601

2.573% 100%

2019 1

24

40,212.50 100%

2019 5 15

22,983 5.08%

2019 3 25

25,500 24,500

79,000 51%

2019 3 27

-1,904 -0.42%

2019 5 24 Fosun Medical Holdings PBM RESP Holdings, LLC Stock Purchase Agreement Fosun Medical Holdings 3,000 PBM RESP Holdings, LLC Breas 20% Fosun Medical Holdings Breas 100% Fosun Medical Holdings

2020 2 28

Breas -5,415 -1.20% Breas

2019 6 25 7

15,666.1412

15,808,417 21.9166%

2019 7 5 “ ” 57,963.30

54,752,824

2018 5 31

2019 7 15

54,752,824

2019 8 8

70,561,242 97.8251%

2,736

0.60%

2019 7 8 Agreement For Sale and Purchase of the Entire Registered Capital Interest in Glaxo Smith Kline Pharmaceuticals (Suzhou) Co., Ltd. 25,000

100%

2019 11 29

358 0.08%

2019 9 30 Ample Up Magnificent View Share Purchase Agreement ,Ample Up 4.02 / Magnificent View Sisram 96,976,000 2019 9 30 21.93%

38,984 Sisram 330,558,800

2019 9 30 74.76%

20 Sisram 2020 3 25

Sisram 15,118

3.34% Sisram

16,200 13,80

-2 0.00%

69,000

100%

2019 2 21 2019 12 13

	-22,999	-5.08%
	40,000	
100%		
2019 2 22 2019 12 16		
	-1,632	-0.36%

ìÍR jK¯ ÍH

-2.94%

(2)

√ □

2019 4 9 ReNeuron License Agreement

ReNeuron

1 CTX 2

hRPC ReNeuron 2,000

20 / /

2019 4 9

100,000 “ ”

2019 11 12 MimiVax License

Agreement MimiVax know-how

SurVaxM

MimiVax 3,800

(3)

	OXFD	OXFD.US	1,678.02	-	-		745.24	-
		002099.SZ	4.62	924,000	657.89		27.72	240.24
		300244.SZ	320.84	5,013,055	11,093.89		12.53	3,489.09
	CHEK	CHEK.US	2,458.44	127,558	153.06		-	-35.16
	CHEKW	CHEKW.US	-	333,334	2.33			-25.12
		HANDA.TW	7,929.46	2,557,775	5,273.46		-	-128.07
	BYSI	BYSI.US	1,091.36	178,923	1,934.71		494.03	-367.76
	AMRX	AMRX.US	43,407.69	3,113,645	10,469.72		-	-18,443.31
		03869.HK	3,399.66	3,030,000	3,257.06		-	-1,404.92

	[1]	002412.SZ	25,621.48	24,263,820	21,279.37		-20.61	1,521.94
	DOVA	DOVA.US	-	-	-		-1,624.70	-
	CFRX	CFRX.US	6,942.59	7,453,857	3,229.17		1.20	-4,597.89
	[2]	300434.SZ	12,705.00	5,507,150	4,212.97		44.06	-633.32
	CURG [3]	CURG.DE	1,721.44	625,357	-		-	-736.82

1 2019 5 29 10 7

2 2019 10 25 “ ” “ ”

3 2019 7 3 Curasan 3 1 CURG 1,876,070 625,357

( )

1 2019 1 15 Sovereign Medical Services, Inc. “ SMS ”

SMS

5% 2019 1 15 4,600

SMS

2 2019 7 30 TPG Healthy, L.P. Plenteous Flair Limited Roberta Lipson HHH NF Unicorn Acquisition L.P. NFC HHH Healthy Harmony GP Transaction Agreement NFC Fosun Rollover Agreement 52,315 10,360,842 HHH Healthy Harmony GP 4.32 42,915 NF 9,400 NFC 940 NFC 940 2019 12 18 NFC 7.16% HHH Healthy Harmony GP 2019 12 18 NFC HHH -4,526 -1.00% 141,908 31.36% NFC

3 2019 9 12 PT Kalbe Genexine Biologics “ Kalbe Genexine ” Binding Term Sheet HLX10 PD-1 Kalbe Genexine

10 1 2 2 3 Kalbe Genexine

2

Kalbe

Genexine 68,200

Kalbe Genexine

3 2019 6 25 “

” 8,499

“ ET-26 ” “ ”

4 2019 11 15

“ ” 49%

198,287,681.82

2019 12 27

84 47

0.01%

( )

√ □

1

			19,654.00	542,168.21	320,600.59	614,363.41	94,847.47	80,620.64
			44,045.54	481,584.72	242,637.90	540,069.04	72,732.99	65,386.06
			51,000.00	304,453.19	221,117.02	220,824.15	25,986.61	22,983.24
Gland Pharma				656,420.11	531,083.09	250,680.00	65,025.25	51,296.81

1

2

			54,349.49	589,981.70	400,041.50	9,092.90	-87,546.50
			5,000.00	245,263.41	169,477.88	160,996.21	21,613.84
Sisram				274,496.73	227,124.14	119,589.98	15,117.60

1

2

3 Sisram

2 10%

10,000 26,984,396.01 7,724,308.66

Et

2019 7 8 Agreement For Sale and Purchase of the Entire Registered Capital Interest in Glaxo Smith Kline Pharmaceuticals (Suzhou) Co., Ltd. 100%

100%

2019 11 20 100%

2019

Nova Medical Israel Ltd.		7,914.71	2,094.03	2019 1 15
		58,909.13	2,736.02	2019 7 15
		25,568.88	358.39	2019 11 29
		3,300.00	-103.32	2019 11 21

2019

2019 1 11

2019 1 17

2019 1 25

2019 4 28

100%

2019 5 15

100%

2019 6 14

2019 7 25

Henlix 2019 8 31

Meistar 2019 9 30

2019 10 22

2019 11 11

100%

2019 12 17

100%

2019

( )

√ □

2020

GDP

2019 “ ”

“ ”

“ ”

“ ”

( )

√ □

2020 “ ”

“

”

“ ”

( )

√ □

2020

2020

2020

5%

2020

1

2

3

4

2020

COVID-19 Gland Pharma

WHO-PQ

“ ” “ ” “ ” “ + ” 2020

2020

me-too, me-better first-in-class, best-in-class PCG

2020

10 SAF-189

2020

2020 Sisram

2020

2020

DRG RBRVS

2020

2020

( )

2020

GMP 25

( )

√ □

1

“ ”

2

ICH

3

1

2 /

/

GMP

3

4

1

ضد ك

□ √

□ √

√ □ HËP4HËHË5eAQ

A

A.

			2019 9 19 12 / A / H 10,000 2019 9 19 2,562,898,545 2% 12 2%	2019 9 19 2020 9 18		

			6 7			

A

			6 7			
A			A A 1 A 2 3 4	2016 2 23 2019 11 8		

2017 1 3

12

U

□ □ √

□ √

□ √

“ ”

□ √

√ □

2018 12 21 —— “ ”

2019 1 1 2019 3 25

2019

2019 1 1

2019 2019

2019 6 2019 2019 16

“ 34 ”

□ √

□ √

□ √

	275
	12
	120
	8

		75
		0
		0

□ √

( )

( )

□ √

( )

√ □

A	2019 4 27 http://www.sse.com.cn

( )

□ √

1

√ □

“ ”	2019 1 7 http://www.sse.com.cn
/	2019 7 6 http://www.sse.com.cn
/	2019 7 31 http://www.sse.com.cn

2

					%	
				26,322.41	2.3997	

				2.17	0.0001	
				357.29	0.0125	
				12.86	0.0004	
				490.60	0.0447	
				100.77	0.0092	
				0.12	0.0000	
				10.92	0.0010	
				323.65	0.0295	
				75.24	0.0069	
				24,538.44	0.8584	
				30,000.00		
				97,953.46		
				18,883.98		
				571.60		

3

√ □

							(%)	
						310.38	0.0109	
						161.96	0.0148	
						2.68	0.0001	
						35.21	0.0012	
						1,415.68	0.0495	
						11.88	0.0004	

						15.85	0.0006	
						13.41	0.0005	
				/	/	1,967.05	0.0780	/

( )

1

√ □

2019 6 5 2019 12 13

3 2019 7 18 Hermed Alpha Industrial Co., Limited

“Hermed” Hinova Pharmaceuticals,Inc. “Hinova” SeriesB

Preferred Shares Purchase Agreement Hermed Hinova

800 Hinova 3,501,190 B

4

□ √

1

√ □

	2019 3 26 http://www.sse.com.cn
	2019 8 27 http://www.sse.com.cn
	2019 11 2 http://www.sse.com.cn

2

□ √

3

√ □

2019 7 15

800

180 180

10% 2019 7 17

1

√ □

	2019 4 16 http://www.sse.com.cn
	2019 9 6 http://www.sse.com.cn

2

3

√ □

1 2019 6 26 Breas Intercompany Loan Agreement Breas 200

2 2019 8 27 Breas Intercompany Loan Agreement Breas 450

3 2019 11 28 Breas Intercompany Loan Agreement Breas 160

2019 1 24 Fosun Pharma Pte. Gland Pharma Dr.P.Ravindranath Amendment NO.1 to the Amended and Restated Shareholders ' Agreement " < > " Fosun Pharma Pte. Gland Pharma Fosun Pharma Pte. 2019 1 24 Gland Pharma 22.08% Gland Pharma 2018 EBITDA

10,371.40 EBITDA 16

20 Gland Pharma

47,000 Fosun Pharma Pte.

Gland Pharma

( )

1

□ √

2

□ √

3

□ √

( )

	0
A	0
	540,929.20
B	1,149,640.21
A+B	1,149,640.21
(%)	36.05
C	0
70% D	22,500
50% E	0
C+D+E	22,500

( )

1.

(1)

□ √

□ √

(2)

□ √

□ √

(3)

□ √

2.

(1)

√ □

		20,000.00	10,000.00	0
		3,000.00	0.00	0
		54,000.00	25,000.00	0
		29,000.00	0.00	0
		7,000.00	3,000.00	0
		18,883.98	18,883.98	0
		21,716.69	14,343.79	0
		3,500.00		

(2)

√ □

		5,000.00	2018/5/4	2019/4/30				4.3500%	71.90			
		5,000.00	2018/5/4	2019/4/30				4.3500%	71.90			
		5,000.00	2019/4/30	2020/4/29				4.3500%	148.63			
		5,000.00	2019/4/30	2020/4/29				4.3500%	148.63			
		3,000.00	2018/3/21	2019/2/18				4.3500%	17.40			
		5,000.00	2016/4/14	2019/4/12				4.7500%	66.63			
		10,000.00	2018/4/28	2019/4/26				4.3500%	138.96			
		10,000.00	2018/4/28	2019/4/26				4.3500%	138.96			
		5,000.00	2019/4/12	2022/4/12				4.7500%	174.17			
		10,000.00	2019/4/26	2020/4/26				4.3500%	302.08			
		10,000.00	2019/4/26	2020/4/26				4.3500%	302.08			
		10,000.00	2018/11/30	2019/5/6				4.3500%	151.04			
		10,000.00	2018/11/30	2019/5/6				4.3500%	151.04			
		1,000.00	2018/12/20	2019/12/23				4.3500%	43.02			
		1,000.00	2018/12/21	2019/12/23				4.3500%	43.02			
		1,000.00	2018/12/21	2019/12/23				4.3500%	43.02			

		3,000.00	2018/9/21	2019/6/28				4.3500%	64.53			
		3,000.00	2018/9/21	2019/9/23				4.3500%	96.06			
		3,000.00	2019/9/21	2019/12/27				4.3500%	130.50			
		4,276.90	2018/3/31	2019/6/21				6.5250%	132.56			
		1,463.00	2018/11/15	2019/11/18				6.5250%	85.12			
		1,633.00	2018/4/16	2019/6/21				6.5250%	50.61			
		741.69	2019/1/15	2020/1/15				6.5250%	47.19			
		2,700.00	2019/5/13	2020/5/12				6.5250%	114.02			
		4,560.60	2019/6/21	2020/3/30				6.5250%	160.36			
		1,721.50	2019/6/21	2020/4/15				6.5250%	60.53			
		1,020.00	2019/7/29	2020/7/29				6.5250%	28.84			
		2,050.00	2019/10/23	2020/10/22				6.5250%	26.01			
		1,550.00	2019/11/15	2020/11/15				6.5250%	13.20			
		1,000.00	2018/8/22	2019/9/20				4.3500%	31.66			
		300.00	2018/11/23	2019/4/28				4.3500%	4.24			
		2,000.00	2018/7/16	2019/3/28				4.3500%	20.78			
		600.00	2018/11/15	2019/10/30				4.3500%	21.90			
		600.00	2019/10/31	2020/10/30				4.3500%	4.50			

		3,000.00	2018/4/3	2021/4/3				4.7500%	144.48			
		3,000.00	2018/2/9	2021/2/9				4.7500%	144.48			
		2,000.00	2018/5/10	2021/5/10				4.7500%	96.32			
		2,000.00	2018/6/29	2021/6/29				4.7500%	96.32			
		1,300.00	2017/11/3	2020/11/3				6.3175%	83.27			
		4,100.00	2016/12/1	2019/12/2				5.2250%	199.35			
		3,800.00	2019/12/2	2022/12/2				5.2250%	16.55			
		2,000.00	2016/4/11	2019/4/11				4.7500%	26.39			
		2,000.00	2016/9/12	2019/9/12				4.7500%	67.03			
		1,000.00	2017/1/18	2020/1/28				4.7500%	48.16			
		1,000.00	2017/2/22	2020/2/22				4.7500%	48.16			
		1,000.00	2017/4/14	2020/4/14				4.7500%	48.16			
		1,000.00	2017/6/15	2020/6/15				4.7500%	48.16			
		1,000.00	2017/8/9	2020/8/9				4.7500%	48.16			
		1,000.00	2017/10/17	2020/10/17				4.7500%	48.16			
		1,000.00	2017/12/4	2020/12/4				5.2250%	52.98			
		500.00	2018/4/12	2021/4/12				5.2250%	26.49			

		4,000.00	2019/1/17	2020/1/17				4.7850%	185.55			
		6,000.00	2019/11/11	2020/11/10				5.2250%	43.15			

(3)

□ √

3.

□ √

( )

1 Gland Pharma

2019 6 25 2018 Gland Pharma

170,444 Gland

Pharma Gland Pharma 1.1%

2019 6 27 Gland Pharma 103

154,950 Gland Pharma 5,420 /

Gland Pharma Gland Pharma Gland Pharma

1%

102 154,650 Gland Pharma 5

Gland Pharma 3,300 Gland Pharma

2

1 2018 7 3 /

2018 7 3 2019 7 2

A / H 10,000

2018 7 3 2,495,060,895 2%

2019 7 2 2018 7 3 2019 7 2

56,287

23,964,300 1,519,800 A 22,444,500 H 2018 7 3

0.96%

2 2019 9 19 /

2019 9 19 2020 9 18

A / H 10,000

2019 9 19 2,562,898,545

2% 12 2%

12,129

5,807,500 H 2019 9 19 0.23%

3

1 2016

“16 01”

2019 3 4 55,000 “16 01”

“16 01” 29,945,000

100

2 2016

2018 4 17

49.60 64,695,400 3,208.89

2019 10 17 49.60 4,366,400

H 210.49

2 2019 12 30 2019 Gland

Pharma Gland Pharma

Gland Pharma

( )

√ □

1.

√ □

2.

√ □

1

2013

—— /

/

71

2

“ ”

1,000 113.7

“ ”

“ ” “ ®

” 11

160

210

11

3

100

20

“ ”

“ ”

“ 99 ” 20

“ -- ” “ ”

4

40

3.

√ □

1.	491
	391.46
1.	
1.1	71
	130
2.	
2.1	589.63
3.	
	40
4.	
4.1	32.74
	149.10

4.

√ □

“ ”

( )

√ □

2019

http://www.sse.com.cn

( )

1.

√ □

(1)

√ □

/

		mg/L	mg/L	t	
		43.2	300	8.61	
		14.3	30	2.85	
		78.5	300	11.14	
		2.2	30	0.31	
		130.5	500	62.48	
		12.23	45	5.85	
		15.25	400	7.30	
		153.94	500	23.81	
		3.39	45	0.52	
		50.08	400	18.32	
		4.04	25	1.48	
		60.97	300	10.92	
		1.65	30	0.30	
		154	500	500.20	
		31	150	100.69	
		96	500	1.91	

			6.9	20	0.40		
	3		0.04	50	0.003		
			105.6	200	4.46		
			4.2	20	0.14		
	1		80.8	400	113.58		
			149.7	400	211.71		
			11.7	80	20.55		
	2		63	120	1.72		

	133		40.42	
	119.5	1,413	819.78	
	260	498.75		

(3)

√ □

“ ”

(4)

√ □

(5)

√ □

/

/

/

3.

□ √

4.

□ √

( )

1

/

/ EHS

EHS

/

2

“

”

3

/ EHS

2019

4,638

4

9,527,926 /

631,436,019 /

+ 7,576,550 GJ/

2.65 GJ/

23,611 /

5

12,483

4,612

7,871

6

/

/ /

7

/

8

9

2019

1

		(%)							(%)
	100,599,031	3.92%				-100,599,031	-100,599,031	0	0
1									
2									
3	100,599,031	3.92%				-100,599,031	-100,599,031	0	0
	100,436,681	3.92%				-100,436,681	-100,436,681	0	0
	162,350	0.01%				-162,350	-162,350	0	0
4									

( )

□ √

□ √

( )

( )

□ √

( )	131,664
( )	139,062

			(%)				
	820,000	938,095,290	36.60	0		0	
HKSCC NOMINEES LIMITED [1]	20,900	551,254,848	21.51	0		-	
005L CT001	-7,477,695	52,401,746	2.04	0		0	
[2]	12,879,207	41,178,552	1.61	0		0	
	0	38,736,157	1.51	0		0	
	31,695,597	31,695,597	1.24	0		0	
	26,631,102	26,631,102	1.04	0		0	
	0	24,067,700	0.94	0		0	
	13,416,424	18,436,018	0.72	0		0	
	-524,535	13,790,532	0.54	0		0	

	938,095,290		

	4 600282 5 300226 6 601969 7 Roc Oil Company Limited 2015 1 8 Luz Saúde, S.A. 2018 11 28 9 Club Med SAS 2015 3 10 Sisram 01696 11 The NAGA Group SA Scale N4G 12 Paris Realty Fund SA PAR 13 01992 14 600655 15 Wolford AG WOL.AV 16 02696 17 TOM TAILOR Holding SE TTI.GY

3

□ √

4

□ √

5

√ □


郭广昌
14.71%
Fosun International Holding Ltd.
100%
复星控股有限公司
70.80%
复星国际有限公司
100%

6

□ √

□ √

□ √

□ √

□ √

Hui												
Hequn Yin			55	2019	2	11	2022	6	24	0	0	0		340.65	
			49	2019	6	25	2022	6	24	50,000	50,000	0		253.10	
			46	2014	9	1	2022	6	24	50,000	50,000	0		263.57	
			50	2016	1	22	2022	6	24	0	0	0		198.85	

	1994 4 00656 01099 01761 600429 02696 NFH NFH 01783 300244
	2010 4 01099 2010 2 12 00980 00363 08247 2004 4 Sisram 01696 02696

	01199 I.T Limited 00999 01728 JS 01691 02208 002202 06869 601869 02208 002202 03866 002948 :02686 00033 ( ) 00846 00993
	Towson University 01099
	688007 TCL 01070 000783
	2011 5 600827 600621
	300290 600874 01065 300363 601866 02866 600018
	2010 1
	2000 5 01099

	02696 000028 CPA ACCA
	2010 6 000607
Aimin Hui	Aimin Hui 2017 11 Aimin Hui 02696 Aimin Hui GE Cephalon,Inc.
Hequn Yin	Hequn Yin 2019 2 Hequn Yin F.Hoffmann-LaRoche Ltd. Novartis Pharmaceuticals Corporation Pfizer Inc.
	2013 1 CLSALimited
	2014 7 Sisram 01696 Pentair Ltd. PNR Pentair Ltd. Suntech Power Holdings Co., Ltd. STP
	2015 10
	2002 5 01099 600511 000950
	2003 7
	2015 11 Sisram 01696
	2017 4 OTC

	2005 2 2000 11 2002 2 Boston University
	2011 6 CPA
	2013 11 300452
	2004 4
	2010 9
	2010 7
	2014 7
	2018 3 01099 Sisram 01696 02696 HR
	2008 10 /
	1995 5 2010 6 2019 6
	2016 6 2020 1
	2018 6 2019 6
	2019 6 2020 1
	2013 6 2019 6
	2016 6 2019 6
	2013 6 2013 6 2019 6
	2011 8 2011 10 2019 6

□ √

			2015 7	
			2017 11	
			2015 7	
			2017 6	2020 2
			2015 11	2019 4

			2015 7	
			2017 3	2020 2
			2020 2	
			2010 5	

			2019 1	
			2011 1 2017 3	

			2018 7	
			2017 4	
			2019 7	
	( )		2012 9	2019 6
			2019 4	
			2019 4	
			2016 2	
	( )		2016 8	
	Healthy Harmony Holdings, L.P.		2017 4	2019 12
	Healthy Harmony GP, Inc.		2017 4	2019 12
	( )		2018 2	
			2018 2	2019 1
			2018 6	2019 12
			2019 3	
			2017 2	
			2017 7	
			2017 4	
			2018 2	2019 1
			2017 5	
			2017 7	
			2017 12	
			2017 9	
			2019 5	
			2018 8	
			2018 4	
			2017 5	
			2019 3	
			2019 11	
			2019 1	
			2019 2	
			2018 12	

			2018 7	
			2018 7	
			2018 8	
			2016 8	
			2018 1	
			2018 2	
			2018 4	
			2017 4	
			2018 5	
			2018 7	
			2018 2	
			2016 12	
			2019 6	
			2005 8	
			2017 3	2020 2
			2020 2	
			2017 3	2020 1
			2017 5	2019 10
			2018 8	2020 1
			2016 5	
			2018 6	
			2012 11	2019 6
			2016 9	
			2013 6	

	9,721.55

√ □

Hequn Yin			

1 2019 2 11 Hequn Yin 2019 2 11

2 2019 6 25 2018

3 2019 6 25

Aimin Hui Hequn Yin

4 2020 1 17

5 2020 1 21

6 2020 1 21

2020 1 21

	162
/	31,208
	31,370
	562
QA QC	16,072
	5,230
	2,147
	724
	1,583
HR	1,070
	4,544
	31,370
	350
	3,312
	10,242
	8,236
	9,230
	31,370





√ □

√ □

2009 2017 ——

“ ” /

2019 / “ ”

“ ” “ ” “ ”

1

3 2019

“ ”

2

2019

/

1-2

3 /

2019 “ ” “

” “ “

4 “ “ /

2019 FoTED

“ ”

□ √

□ √

2019	2019 3 22	(http://www.sse.com.cn)	2019 3 23
2018 2019 A 2019 H	2019 6 25	(http://www.sse.com.cn)	2019 6 26
2019	2019 10 21	(http://www.sse.com.cn)	2019 10 22
2019	2019 12 30	(http://www.sse.com.cn)	2019 12 31

								/ 3
								/
		17	17	12	0	0		6
		17	17	15	0	0		1
		17	17	12	0	0		5
1		9	9	9	0	0		0
		17	17	17	0	0		0
		17	17	14	0	0		4
		17	17	17	0	0		0
1		9	9	8	0	0		1
1		9	9	7	0	0		0
2		8	8	8	0	0		0
		17	17	17	0	0		0
2		8	8	8	0	0		0
1		9	9	9	0	0		0
2		8	8	6	0	0		4

[2]		8	8	8	0	0		3

	17
	12
	5

□ √

□ √

√ □

ḍ tc q

╥ q 9 ɾ c ł

3

2 1

4

5

1 2019 2023

□ √

□ √

√ □

2020 3 31

http://www.sse.com.cn

□ √

√ □

http://www.sse.com.cn

2016	16 01	136236	2016/3/4	2021/3/4	29.945[1]	4.50[2]		
2017	17 01	143020	2017/3/14	2022/3/14	12.5	3.48[3]		
2018	18 01	143422	2018/8/13	2023/8/13	13	5.10		
2018	18 02	155067	2018/11/30	2022/11/30	5	4.47		
2018	18 03	155068	2018/11/30	2023/11/30	10	4.68		

1 “16 01” 30 2016
2019 3 4
55,000 “16 01” “16 01”
29.945

2 2016
2019 3 4 “16 01” 3.35%
4.50%

3 2017
2020 3 14 “17 01” 4.50%
3.48%

1 2019 3 4 “16 01”

2 2019 3 14 “17 01”

3 2019 8 13 “18 01”

4 2019 12 2 “18 02”

5 2019 12 2 “18 03”

6 2020 3 4 “16 01”

7 2020 3 16 “17 01”

1 “16 01” 2016 3 4 30
2017 3 15 2019 3 4
55,000 “16 01” “16 01”
29.945
2 “17 01” 2017 3 14 12.5
2017 3 15
3 “18 01” 2018 8 15 13
2018 8 15
4 “18 02” 2018 12 4 5
2018 12 4
5 “18 03” 2018 12 4 10
2018 12 4

		5 15
		010-88027267
		398 14

16 01	30	0	30	
17 01	12.5	0	12.5	
18 01	13	0	13	
18 02	5	0	5	
18 03	10	0.5	10	

1 “16 01”

2018 /

2018 “16

01”“17 01”“18 01”“18 02” “18 03” 2018

2

√ □

	2019	2018	%	
	7,120,921,606.41	5,856,166,761.25	21.60	
	1.17	1.00	17.00	
	0.94	0.82	14.63	
	48.50	52.39	-3.89	
	19.29%	15.85%	3.44	
	5.12	4.81	6.44	
	4.83	5.61	-13.90	
	6.51	6.25	4.12	
	100	100	0.00	
	100	100	0.00	

√ □

1 2019 10 18 2019

2 2019 10 25 2019

3 2019 12 13 2019 .

√ □

483

142

□ √

□ √

6 CX × Û €

B %

B %

B %

B %

B %

B %

0 €˜1)m Đ ™P 0 €

#wCU F3“0 ™S £ 0 0 ð M”#w ÞCUFH ,7,

)™ 2 Ä 0 ð • 1)• FH , l- 0B7 0)—

3 ´

$ +

3 ´

3 ´

3 ´

D

E

H ~ Q 9i

AĐˆˆ bAĐ

> @
> @

u ’Æ $y † Hy 3ó 0 S Dˆ 33Dˆ 3330 VË P uEv•’` 0 Àu ’Á Q03 $€ € X (Dˆ Dˆ 3330 VË P uEv•’` 0

±

±

±

*ODQG 3KDUPD /LPLWHG

> @

ŽCc < 0 p

1DWXUHV 6XQVKLQH 3URGXFWV ,QF

1HZ)URQWLHU +HDOWK
&RUSRUDWH 2IILFH
+$5021< +2/',1*6 / 3

6RYHUHLJQ 0HGLFDO 6HUYLFHV OQF
³606´
$PHULJHQ 3KDUPDFHXWLFDOV /WG
³$0*´

1DWXUHV 6XQVKLQH 3URGXFWV ,QF

+($/7+< +$5021<
+2/',1*6 / 3

6' %LRVHQVRU ,QF
6RYHUHLJQ 0HGLFDO 6HUYLFHV OQF
³606´
$PHULJHQ 3KDUPDFHXWLFDOV /WG
³$0*´
$PEU[,QF

606
$0*
(26 ,PDJLQJ

V)– 5 @ 20

*03

*03

*03

*03

*03

I•`ÐQR K6 d ‰ y ™•[R¸P

P ™€ p

>

2

2

2

¢ .K6 ' N@¿ @ 0

%UHDV

%UHDV

2

2

2

$OPD
$OPD

$OPD
1RYD 0HGLFDO ,VUDHO /WG
$OPD
$OPD
$OPD

%UHDV
%UHDV

9LYR
%UHDV
%UHDV
%UHDV

$OPD /DVHUV /WG

_____

_____

- & ,

- & ,

_____

a a a ™˜ B 8 ñ7`U!J

a

a

@p2 @D @p @p b b s( )SƐƐbAEVA@)i)(A " D bA b @ VA@b b #T b #T 0b@b@b @ bA b b VA@°u b Ó B"M Y–

3UDPHULFD)RVXQ &KLQD 2SSRUV

)XQG / 3 OPDOPD /DVHU ,QF

a

a

1# / Y• ñP@Ð À

Ð 0

$

$

$

ﻫ •b

ﻫ •€

)•

$OPD	$OPD
%UHDV	%UHDV
7ULGHP	7ULGHP
*ODQG	*ODQG

+.

&KLQGH[0HGLFDO /LPLWHG
&0/ +.

$OPD /DVHUV /WG
³$OPD´

%UHDV 0HGLFDO +ROGLQJV $%
%UHDV
*ODQG 3KDUPD /LPLWHG
*ODQG
7ULGHP 3KDUPD 6 $ 6
7ULGHP

5LFKDUG /LTXQ
:DQJ

1DWXUH¶V 6XQVKLQH
3URGXFWV ,QF 163

1HZ)URQWLHU +HDOWK
&RUSRUDWLRQ 1)+
$PHULJHQ 3KDUPDFHXWLFDOV /WG 'DUULQ 3UHVFRWW
6RYHUHLJQ 0HGLFDO 6HUYLFHV OQF -RQK + +DMMDU 0 '

6DODGD[%LRPHGLFDO ,QF 6DODGD[
:H 'RFWRU *URXS /LPLWHG

'DYLG -RVHSK
5RVD
'DYLG -RVHSK
5RVD

x

x

x

x
x
x

x
x
x

x

x

x

%U H D V
*O D Q G
1R Y D



D

* O D Q G & K H P L F D O V E

6 D O D G 0 € • 3330 ÃT$6V5wcecWv7•# 2À9 0

G
H

+ + +

I

,QWHJUDWHG (QGRVFRS\

*ODQG &KHPLFDOV

D

D

E *ODQG &KHPLFDOV

F

G

H

I

D

E 'KDQDQMD\D
6DVLNDOD

+ + +

*ODQG &KHPLFD

*ODQG &KHPLFDOV		
+++		

+ + +

1DWXUH V 6XQVKLQH)DU (DVW /LPLWHG

1DWXUH V 6XQVKLQH)DU (DVW /LPLWHG

)RVXQ ,QGXVWULDO1DWXUH/LPLWHG6XQVKLQH)DU (DVW /L

$ +

$

$

$

$

$

$

$

$

$

$

*ODQG

&(

%LR17HFK 6(P51$

&29,'

3 ´

P 0 P 0 ‰ € @ @ P 0

1DWXUH¶V 6XQVKLQH
3URGXFWV ,QF

6RYHUHLJQ 0HGLFDO 6HUYLFHV ,QF

&0) +HDOWK

,QYHVWPHQW *3 /WG

E >V#ÐM0

™cU0 (ð ð @ ` 0 ¡• Ð P (

9vÐ ° ð • •—(P ° P ¢ @1R

1\ q ¼8² 7 · &- …

7 · &- …	0 Æ- 9# Ê >˜ ê Ãk1Ñ JAÑ ŒCOCS ê ÃJAÑ j ´COCS ê1® = ¦- 1 ,´CR Ñ Õ>˜ ×
7 · &- …	¼ ÃE- 9 JAÑ 8 » Ñ p- 1 Ã# ¼ JAÑ 81® = ¦- 1 ,´ ÑAÑ Õ z Ï & ×

7 · &- …